Totus Medicines Secures Series B Funding to Accelerate Drug Development
Totus Medicines, guided by the leadership of DCVC Bio and joined by North Pond Ventures, Camford Capital, and the Regents of the University of Minnesota, has successfully closed its Series B funding.
The investment will be channeled into advancing the company’s clinical program, expanding the pipeline, and further developing its pioneering platform.
Revolutionizing Drug Discovery with Innovative Technology
At the forefront of Totus Medicines’ approach is the integration of a groundbreaking DNA-encoded covalent library technology with artificial intelligence and machine learning (AI/ML). This unique fusion enables the discovery and development of small molecule medicines.
The company’s platform possesses the capability to efficiently screen billions of potential drug candidates against multiple targets simultaneously. This unparalleled technology aims to outpace traditional methods, potentially unlocking drug candidates even for currently deemed “undruggable” targets.
Leadership Transition and Visionary Appointment
Totus Medicines also announced the appointment of Dr. Nassim Usman as President and Chief Executive Officer. Dr. Usman brings a wealth of expertise, previously serving in executive positions at Catalyst Biosciences and demonstrating prowess in C-suite management, board memberships, and venture capital involvement.
His extensive background includes steering drugs into clinical development, orchestrating licensing deals, and securing funding through various financing routes. Dr. Neil Dhawan, Totus co-founder, will transition into the role of Chief Scientific Officer and Head of R&D, continuing to oversee the company’s platform, programs, and data.
Dr. Usman’s Accomplishments and Expertise
Dr. Usman’s professional journey spans significant achievements in drug development, financial leadership, and investment endeavors.
With his academic foundation in Organic Chemistry from McGill University and a post-doctoral fellowship at MIT, he has shaped his career by contributing to several successful biotech ventures, leading clinical advancements, and fostering strategic alliances within the industry.
Funding Injection for Innovative Drug Discovery
With the Series B funding, Totus Medicines is poised to drive forward its vision of transforming drug discovery through technology-driven innovation, leveraging AI/ML and DNA-encoded libraries to potentially revolutionize the landscape of small molecule medicines.
Share on Facebook «||»
Share on Twitter «||»
Share on Reddit «||»
Share on LinkedIn
Axelspace Secures $44M in Series D Funding to Propel Micro-Satellite Technology Expansion: Axelspace, a prominent player in micro-satellite technology, has successfully garnered support from a consortium of backers in its latest funding round. Notable contributors include Sumitomo...
NeoCarbon Secures €3.2M Seed Funding Led by RAISE Seed For Good to Propel Groundbreaking CO2 Removal Technology: Investment Round Led by RAISE Seed For Good: RAISE Seed For Good has taken the lead in a funding round for NeoCarbon, with additional contributions...
Simply Homes Secures Funding to Propel Affordable Housing Solutions Across the Midwest: Simply Homes Secures Funding to Tackle Affordable Housing Crisis Simply Homes, a proponent of addressing the affordable housing crisis, has successfully raised funds in a...
Vasa Secures Funding Round Led by Orphinic Scientific to Propel Cardiovascular Therapie: Orphinic Scientific Leads Investment Round in Vasa In a funding round spearheaded by Orphinic Scientific, Vasa, a biopharmaceutical company, has secured investments from private investment...
Deeploi Secures Funding to Propel Growth in IT Management Solutions: Investment Leadership and Board Inclusion: In a recent funding round, deeploi, a burgeoning IT management platform, secured a significant investment led by Atomico, with participation...
dataroomHQ Secures $3.5M Funding to Propel AI-Powered Platform: dataroomHQ, led by CEO & Founder Jeff Schwartz, has successfully raised $3.5 million in a funding round, marking a significant milestone for the company’s growth...
Health Advance Partners Leads Pre-Seed Funding Round for SingleTimeMicroneedles’ Innovative Drug Delivery Technology: SingleTimeMicroneedles (STM), a biotech company specializing in drug and vaccine delivery, has announced a successful pre-seed funding round. The funding round was led by Health...
Marama Labs Secures Significant Funding Round Led by The Yield Lab, Attracting Global Investors for its Innovative UV-Vis Spectroscopy Technology: The Yield Lab Leads Major Funding Round for Marama Labs’ Deep-Tech Innovations In a groundbreaking development for deep-tech sensor and data analytics firm Marama Labs,...
PulmoBioMed Secures £1.4M Funding for Innovative Breath Sampling Technology: PulmoBioMed, a pioneering company in the field of breath sampling technology, has successfully raised £1.4 million in a funding round, marking a significant milestone for...
AlensiaXR Secures Series A Funding to Accelerate Advancements in HoloAnatomy® Learning Platform: In a recent funding round, AlensiaXR has successfully secured significant investments, with Sopris Capital at the forefront, accompanied by contributions from the Healthcare Collaboration Fund...